search

Active clinical trials for "Glomerulonephritis, Membranous"

Results 61-70 of 98

Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC

Idiopathic Membranous NephropathyTacrolimus1 more

We propose hyperspectral imaging analysis as a method to identify the efficacy of hormone-tacrolimus therapy for PMN, and to classify sensitive and insensitive patients treated with hormone-tacrolimus regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.

Not yet recruiting10 enrollment criteria

Prognostic Model of GC/TAC in the Treatment of MN

Idiopathic Membranous Nephropathy

The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + tacrolimus. The main questions it aims to answer are: to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of glucocorticoid + tacrolimus to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard the treatment of glucocorticoid + tacrolimus treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy. Researchers will compare [remission group and non-remission group] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.

Not yet recruiting8 enrollment criteria

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous...

Lupus Membranous Nephropathy

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).

Completed11 enrollment criteria

A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy

Glomerulonephritis

Membranous Nephropathy (MN) is an immune-mediated kidney disease that affects the glomerulus or the filter that removes toxins from the blood. Damage to the membrane that separates blood from urine results in loss of protein into the urine (proteinuria) and in some cases loss of kidney function.There is no standard specific treatment for MN. ACTH has a pronounced lipid-lowering effect in healthy individuals, in steroid-treated patients with renal disease and in hemodialysis patients Some studies suggest that prolonged synthetic ACTH therapy may represent an effective therapy in patients with idiopathic MN, more extensive randomized studies with longer follow-up are needed before therapeutic recommendations can be made. We propose to do a pilot study to test the hypothesis that biologic ACTH, a slow-release formulation of corticotropin extracted from porcine pituitary glands (H.P. Acthar gel) will be effective in reducing proteinuria and improving lipid profile in patients with idiopathic MN.

Completed11 enrollment criteria

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy

This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study.

Completed14 enrollment criteria

A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis...

Lupus NephritisGlomerulonephritis1 more

This is a prospective randomized open-label pilot study to compare mycophenolate mofetil in combination with corticosteroid treatment and tacrolimus in combination with corticosteroid treatment in membranous lupus nephritis. The change in urine protein excretion will be the primary outcome studied. The study duration will be 24 months for each patient.

Completed1 enrollment criteria

Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy

The purpose of this study is: To explore the potential role of tacrolimus in the treatment of membranous nephropathy. To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.

Completed9 enrollment criteria

Mycophenolate Mofetil in Membranous Nephropathy

GlomerulonephritisMembranous

Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects. In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.

Completed10 enrollment criteria

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

Nephrotic SyndromeMembranous Nephropathy

This phase I study is a single arm, multi-dose study that will evaluate steady-state apixaban pharmacokinetics (PK) and pharmacodynamics (PD) in subjects with Nephrotic Syndrome (NS) vs healthy control subjects. This study will enroll 20 subjects diagnosed with NS and 10 healthy control subjects. Comparing differences in steady-state apixaban PK/PD parameters between subjects with NS and healthy volunteers will be essential to identifying a safe and effective apixaban dose and dose administration schedule for future randomized controlled trials (RCTs).

Completed28 enrollment criteria

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus...

Idiopathic Membranous Nephropathy

The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy. To investigate the safety and tolerability of Tripterygium wilfordii plus steroid

Completed9 enrollment criteria
1...678...10

Need Help? Contact our team!


We'll reach out to this number within 24 hrs